Across TCGA pan-cancer cohorts, GM2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GM2A data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GM2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GM2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where GM2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.911	0.434	.010	11	view →
PDAC	OS	Median	II,III,IV	0.920	0.763	.027	5	view →
UCEC	OS	Median	All	1.000	0.909	.013	4	view →
LSCC	DFS	Median	II,III,IV	0.989	0.838	.024	3	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.879	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GM2A tumor-vs-normal RNA expression · all GM2A data types